AbbVie (NYSE:ABBV) Trading Down 1% on Insider Selling

AbbVie Inc. (NYSE:ABBV) was down 1% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $223.23 and last traded at $227.7470. Approximately 7,788,091 shares traded hands during trading, an increase of 8% from the average daily volume of 7,210,244 shares. The stock had previously closed at $230.11.

Specifically, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Citigroup reduced their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a report on Tuesday, January 20th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase 1 ABBV‑295 (long‑acting amylin analog) showed clinically meaningful weight loss (~7.8–9.8% at week 12/13) with favorable tolerability, supporting continued development as a non‑incretin obesity option. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
• Positive Sentiment: Positive Phase 3 AFFIRM topline results for risankizumab (SKYRIZI) in Crohn’s disease point to label expansion and incremental sales upside for an already commercialized franchise. AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: Analyst support: J.P. Morgan reiterated a Buy rating, which reinforces investor confidence in AbbVie’s mix of cash flow, dividend, and pipeline optionality. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Positive Sentiment: Industry coverage notes ABBV‑295’s competitive profile vs. GLP‑1/GIP approaches, which could drive differentiated positioning if later‑stage data hold up. AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
• Neutral Sentiment: Analyst / media attention (Zacks, Yahoo) is elevating interest in ABBV as a momentum/dividend name, but these are background supports rather than immediate catalysts. Here’s Why AbbVie (ABBV) is a Strong Momentum Stock
• Neutral Sentiment: Broader write‑ups synthesize recent trial updates into AbbVie’s valuation/growth outlook — useful context but not a single-day catalyst. AbbVie Trial Updates Add Context To Valuation And Growth Outlook
• Negative Sentiment: Despite positive ABBV‑295 numbers, shares fell after the readout — investors may be disappointed relative to expectations versus GLP‑1/GIP therapies or are focusing on pathway uncertainty and commercialization risk. AbbVie’s Early Obesity Drug Data Shows Up To 10% Weight Loss
• Negative Sentiment: ICER will review AbbVie’s Parkinson’s drug — a health‑economics review can lead to pricing/reimbursement pressures if cost‑effectiveness is questioned. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Corporate/financial items: an SVP sold about $1.22M of stock and AbbVie has tied roughly $350M to the amylin program — insider selling and program commitments can be read as modest near‑term negatives for sentiment or cash deployment. AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock AbbVie ties $350m amylin bet to almost 10% weight loss after 12 weeks

AbbVie Stock Performance

The company’s 50 day simple moving average is $224.66 and its 200-day simple moving average is $224.33. The firm has a market capitalization of $402.70 billion, a PE ratio of 96.50, a PEG ratio of 0.80 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 earnings per share. The business’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ABBV. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the 2nd quarter worth $26,000. Chelsea Counsel Co. bought a new position in AbbVie in the third quarter valued at $26,000. Litman Gregory Wealth Management LLC purchased a new stake in AbbVie during the fourth quarter valued at about $28,000. Westend Capital Management LLC bought a new stake in AbbVie during the fourth quarter worth about $29,000. Finally, Imprint Wealth LLC lifted its stake in AbbVie by 56.3% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.